Literature DB >> 23701705

Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure.

Toshihiro Nishizawa1, Hidekazu Suzuki, Masahiko Takahashi, Masayuki Suzuki, Toshifumi Hibi.   

Abstract

BACKGROUND AND AIM: The interval between first-line Helicobacter pylori eradication treatment and second-line treatment may be critical to the second-line therapeutic effect. We attempted to assess the association between the second-line eradication rates and the treatment interval.
METHODS: Data of patients, who were administered the second-line H. pylori eradication regimen at Tokyo Medical Center between 2008 and 2012, were reviewed.
RESULTS: Of the 148 patients enrolled, one patient dropped out. The eradication rates were 88.6% (intention-to-treat [ITT]) and 89.3% (per-protocol [PP]) for early eradication group (eradication interval < 180 days, patients number 132) and 68.8% (ITT and PP) for delayed eradication group (eradication interval ≥ 180 days, patients number 16). The eradication rate in the delayed eradication group was significantly lower than in the early eradication group (P = 0.027 [ITT] and 0.021 [PP]). The eradication interval in the subjects showing eradication failure (124.0 ± 96.8 days, patients number 19) was significantly longer than those showing successful eradication (85.8 ± 56.9 days, patients number 128, P = 0.008).
CONCLUSION: Our results suggest that the delay of second-line treatment should be avoided.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Helicobacter pylori; eradication; interval

Mesh:

Substances:

Year:  2013        PMID: 23701705     DOI: 10.1111/jgh.12281

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

2.  Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial.

Authors:  Daniela Munteanu; Ohad Etzion; Gil Ben-Yakov; Daniel Halperin; Leslie Eidelman; Doron Schwartz; Victor Novack; Naim Abufreha; Pavel Krugliak; Alexander Rozenthal; Nava Gaspar; Alexander Moshkalo; Vitaly Dizingof; Alexander Fich
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

3.  Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Ai Fujimoto; Hiroto Kinoshita; Shuntaro Yoshida; Yoshihiro Isomura; Akira Toyoshima; Takanori Kanai; Naohisa Yahagi; Osamu Toyoshima
Journal:  J Clin Biochem Nutr       Date:  2017-02-16       Impact factor: 3.114

4.  A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H pylori.

Authors:  Toshihiro Nishizawa; Kosuke Sakitani; Hidekazu Suzuki; Tadahiro Yamakawa; Yoshiyuki Takahashi; Nobutake Yamamichi; Hidenobu Watanabe; Yasuyuki Seto; Kazuhiko Koike; Osamu Toyoshima
Journal:  United European Gastroenterol J       Date:  2019-01-15       Impact factor: 4.623

5.  Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Masahide Arita; Yosuke Kataoka; Kazushi Fukagawa; Daisuke Ohki; Keisuke Hata; Toshio Uraoka; Takanori Kanai; Naohisa Yahagi; Osamu Toyoshima
Journal:  J Clin Biochem Nutr       Date:  2018-06-20       Impact factor: 3.114

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.